Anti-Human RP105 (NT)
| Code | Size | Price |
|---|
| LEI-R1247-20ug | 20 ug | £199.00 |
Quantity:
| LEI-R1247-0.1mg | 0.1 mg | £591.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Shipping:
Ambient
Storage:
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Further Information
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen:
PN:R1250
Long Description:
Toll-like receptors (TLRs) are evolutionarily conserved pattern-recognition molecules resembling the toll proteins that mediate antimicrobial responses in Drosophila. These proteins recognize different microbial products during
infection and serve as an important link between the innate and adaptive immune responses (1,2). The signaling of these TLRs is kept under tight control by the
expression of endogenous inhibiting proteins. One such protein is RP105, a recently identified homolog to TLR4 that, with MD-1, interacts with and inhibits the TLR4/MD-2 signaling pathway (3). It has also been suggested that the
RP105/MD-1 complex influences antibody production mediated by both TLR4/MD-2 and TLR2 receptor complexes (4). Despite its predicted molecular weight, RP105 often migrates at 95 ? 105 kDa.
Target:
RP105
References
1. Takeda, K. et al.(2003) Annu. Rev. Immunol. 21:335-76. 2. Janeway Jr., CA. and Medzhitov, R. (2002) Annu. Rev. Immunol. 20:197-216. 3. Divanovic, S. et al. (2005) J. Endotoxin Res. 11:363-8. 4. Nagai, Y. et al. (2005) J. Immunol. 174:7043-9.
Related Products
| Product Name | Product Code | Supplier | Anti-Human RP105 (CT) | LEI-R1245 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Human RP105 (Intermediate Domain) | LEI-R1246 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RP105 (CT) Blocking Peptide | LEI-R1248 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RP105 (Intermediate Domain) Blocking Peptide | LEI-R1249 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RP105 (NT) Blocking Peptide | LEI-R1250 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||